Bulk Pharmaceutical API Sources for XTAMPZA ER

Bulk Pharmaceutical API Sources for XTAMPZA ER

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-16043
Sigma-Aldrich		O-002_CERILLIAN
LGC Standards		LGCAMP0672.10-01
LGC Standards		LGCAMP0672.10-02
LGC Standards		LGCFOR0672.10

XTAMPZA ER Bulk Active Pharmaceutical Ingredient (API) Supply Chain Analysis

Last updated: February 19, 2026

XTAMPZA ER (controlled-release oxycodone), a Schedule II controlled substance, is manufactured by Palatin Technologies and marketed by Amylin Pharmaceuticals. The bulk API sourcing strategy for XTAMPZA ER involves a multi-faceted approach, prioritizing regulatory compliance, supply chain security, and cost-efficiency. This analysis details current and potential API sources, manufacturing capabilities, and associated risks.

What is the primary bulk API for XTAMPZA ER?

The primary bulk Active Pharmaceutical Ingredient (API) for XTAMPZA ER is oxycodone hydrochloride. Oxycodone is a semi-synthetic opioid analgesic used to manage moderate to severe pain. The controlled-release formulation of XTAMPZA ER modifies the release profile of oxycodone, providing extended pain relief.

Oxycodone Hydrochloride Specifications

• Chemical Name: 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride
• CAS Number: 125-23-5
• Molecular Formula: C₁₈H₂₁NO₄ • HCl
• Molecular Weight: 351.82 g/mol
• Physical Appearance: White to off-white crystalline powder
• Solubility: Freely soluble in water, soluble in alcohol, practically insoluble in ether.
• Purity Standards: Must meet United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) monographs.
• Impurities: Strict limits on related substances, residual solvents, and heavy metals.

Who are the key current suppliers of oxycodone hydrochloride API?

The global market for oxycodone hydrochloride API is consolidated, with a limited number of major manufacturers holding significant market share. These suppliers are subject to stringent regulatory oversight by agencies such as the U.S. Drug Enforcement Administration (DEA) and the International Narcotics Control Board (INCB) due to the controlled nature of the substance.

Key current suppliers include:

• Mallinckrodt Pharmaceuticals: A prominent supplier of opioid APIs, including oxycodone. They operate under strict DEA quotas and adhere to rigorous quality control standards. Their manufacturing facilities are located in the United States and the United Kingdom.
• Perrigo Company: While known for its generic pharmaceuticals, Perrigo also manufactures and supplies APIs, including controlled substances, to the pharmaceutical industry. Their operations are global, with significant API manufacturing sites in North America and Europe.
• Actavis Elizabeth LLC (a subsidiary of Teva Pharmaceutical Industries): Teva is a major global pharmaceutical company with API manufacturing capabilities. Actavis Elizabeth has historically been a supplier of opioid APIs in the U.S. market.
• Noramco, Inc. (a Johnson & Johnson company): Noramco is a leading producer of controlled substance APIs, including oxycodone, with manufacturing facilities in the United States. They emphasize secure supply chains and regulatory compliance.

These suppliers are required to maintain DEA registration and operate under annual aggregate production quotas (APQs) established by the DEA for Schedule II controlled substances.

What are the regulatory requirements for sourcing oxycodone hydrochloride API?

Sourcing oxycodone hydrochloride API is governed by a complex web of international and national regulations designed to prevent diversion and abuse. These regulations impact every stage of the supply chain, from manufacturing to import/export.

Key regulatory considerations include:

• DEA Registration and Quotas: Manufacturers and distributors of Schedule II controlled substances in the U.S. must be registered with the DEA. Annual aggregate production quotas (APQs) are set by the DEA for each controlled substance, limiting the total amount that can be manufactured or imported into the U.S. each year. API suppliers must operate within these quotas.
• International Narcotics Control Board (INCB): The INCB monitors the implementation of UN drug control conventions. Manufacturers and distributors involved in international trade of controlled substances must comply with INCB regulations, including import and export authorizations.
• FDA Oversight: The U.S. Food and Drug Administration (FDA) oversees the quality and manufacturing practices of API suppliers through Good Manufacturing Practices (GMP) regulations. Facilities are subject to FDA inspections.
• State Regulations: Individual U.S. states may have additional licensing and reporting requirements for the handling of controlled substances.
• Traceability and Security: Robust systems for tracking and securing the API throughout the supply chain are mandated. This includes secure storage, transportation, and record-keeping to prevent theft and diversion.
• International Import/Export Controls: For import into the U.S., the DEA must approve import quotas. For export, both the exporting and importing countries' regulatory bodies must grant authorizations.

The complexity of these regulations necessitates that API suppliers have established robust compliance programs and secure supply chain management systems.

What are the potential risks associated with current oxycodone hydrochloride API sourcing?

The concentrated nature of the oxycodone hydrochloride API market and the stringent regulatory environment present several significant risks for XTAMPZA ER manufacturers.

Potential risks include:

• Supply Chain Disruptions: Reliance on a limited number of suppliers makes the supply chain vulnerable to disruptions. These can arise from:
  • Manufacturing issues (e.g., quality control failures, equipment malfunctions).
  • Regulatory enforcement actions (e.g., plant shutdowns, import/export restrictions).
  • Geopolitical instability in regions where API manufacturing is concentrated.
  • Natural disasters impacting manufacturing facilities or transportation routes.
• DEA Quota Limitations: The DEA's APQs can limit the total available supply of oxycodone API. If demand for XTAMPZA ER exceeds the allocated quota for its API suppliers, it could lead to shortages.
• Price Volatility: Limited supplier competition can lead to price fluctuations. Increased regulatory compliance costs or raw material costs can be passed on to API purchasers.
• Quality and Compliance Issues: A failure by an API supplier to meet GMP standards or other regulatory requirements can result in batch rejections, product recalls, and potential supply interruptions. Auditing and qualification of suppliers are critical.
• Diversion and Security Threats: Despite stringent controls, the risk of diversion of controlled substances from the legitimate supply chain remains a concern. Manufacturers must ensure their suppliers have robust security protocols.
• Increased Scrutiny and Litigation: The ongoing opioid crisis has led to heightened scrutiny of all parties involved in the opioid supply chain. This can translate to increased legal risks and reputational damage.

What are alternative or emerging sourcing strategies for oxycodone hydrochloride API?

While the market for oxycodone hydrochloride API is established, pharmaceutical companies explore strategies to mitigate sourcing risks and ensure long-term supply stability.

Emerging and alternative sourcing strategies include:

• Diversifying Supplier Base: Actively seeking and qualifying secondary or tertiary API suppliers, even if they currently hold smaller market shares. This requires thorough due diligence regarding their regulatory compliance, manufacturing capacity, and quality systems. Companies may engage with API manufacturers in different geographic regions to reduce geopolitical risk.
• Vertical Integration (Limited Applicability): While full vertical integration (manufacturing the API in-house) is rare for controlled substances due to the significant regulatory and infrastructure hurdles, some larger pharmaceutical companies may explore partnerships or joint ventures to gain more control over specific stages of the API production or secure dedicated supply.
• Developing Alternative Synthesis Pathways: Research into novel or more efficient synthetic routes for oxycodone that may utilize more readily available precursors or reduce reliance on specific raw material suppliers. This is a long-term R&D strategy.
• Strategic Stockpiling: Maintaining strategic reserves of the API, within regulatory limits for storage of controlled substances, to buffer against short-term supply disruptions.
• Long-Term Supply Agreements: Negotiating multi-year contracts with existing or new suppliers that include provisions for guaranteed supply, price stability, and quality assurance. These agreements often require significant commitments from both parties.
• Engaging with API Manufacturers in Emerging Markets: While the established players dominate, exploring API manufacturers in regions with growing pharmaceutical manufacturing sectors. This requires rigorous qualification to ensure they meet the high standards of Western regulatory agencies (FDA, EMA). Examples include manufacturers in India or certain Eastern European countries, provided they meet stringent GMP and regulatory requirements.

What are the considerations for qualifying new oxycodone hydrochloride API suppliers?

Qualifying a new supplier for an API as critical and regulated as oxycodone hydrochloride requires a comprehensive and meticulous process.

Key considerations for supplier qualification include:

• Regulatory Compliance:
  • DEA Registration: Verification of current and valid DEA registration for handling Schedule II controlled substances.
  • FDA/EMA Inspection History: Review of recent inspection reports and any outstanding regulatory actions from relevant health authorities.
  • GMP Adherence: Confirmation that the supplier's manufacturing facilities and quality systems operate in full compliance with current Good Manufacturing Practices (cGMP).
  • INCB Compliance: For international suppliers, confirmation of adherence to INCB regulations for international trade.
• Manufacturing Capabilities and Capacity:
  • Production Volume: Assessment of the supplier's ability to consistently produce the required volumes of oxycodone hydrochloride API to meet demand.
  • Process Robustness: Evaluation of the manufacturing process for consistency, scalability, and control of critical parameters.
  • Technology and Equipment: Review of the technology and equipment used, ensuring they are up-to-date and capable of producing API meeting stringent specifications.
• Quality Management System (QMS):
  • Robustness: Detailed audit of the supplier's QMS, including change control, deviation management, CAPA (Corrective and Preventive Actions), complaint handling, and batch release procedures.
  • Analytical Capabilities: Verification of the supplier's in-house analytical testing capabilities and validation of their methods.
  • Stability Programs: Review of the supplier's API stability testing programs to ensure shelf-life is adequately established and maintained.
• Supply Chain Security and Traceability:
  • Security Measures: Assessment of physical security measures at manufacturing and storage sites to prevent theft and diversion.
  • Logistics and Transportation: Evaluation of their logistics partners and transportation methods for secure and compliant movement of the API.
  • Traceability Systems: Confirmation of robust systems for tracking API from raw materials through to finished product delivery.
• Financial Stability and Business Continuity:
  • Financial Health: Assessment of the supplier's financial stability to ensure their long-term viability as a supplier.
  • Business Continuity Plans: Review of their plans for managing disruptions (e.g., natural disasters, geopolitical events) that could impact supply.
• Environmental, Social, and Governance (ESG) Factors: Increasingly, companies consider a supplier's commitment to sustainable practices and ethical operations as part of their overall risk assessment.
• Intellectual Property (IP) Considerations: For any novel synthesis pathways or process improvements, careful consideration of IP ownership and freedom to operate is essential.

A thorough supplier qualification process typically involves on-site audits, extensive documentation review, and potentially pilot batch production runs.

Key Takeaways

XTAMPZA ER's bulk API, oxycodone hydrochloride, is sourced from a limited number of highly regulated global manufacturers. Key suppliers include Mallinckrodt Pharmaceuticals, Perrigo Company, Actavis Elizabeth LLC, and Noramco, Inc. Sourcing is governed by stringent DEA and INCB regulations, including aggregate production quotas, which present inherent supply risks. Potential risks include supply chain disruptions, quota limitations, price volatility, and quality control failures. Mitigation strategies involve diversifying the supplier base, exploring long-term supply agreements, and potentially developing alternative sourcing or manufacturing approaches. Rigorous qualification of any new API supplier is paramount, focusing on regulatory compliance, manufacturing capabilities, robust quality systems, and supply chain security.

FAQs

1. What is the primary risk associated with the current supply of oxycodone hydrochloride API? The primary risk is the reliance on a limited number of DEA-regulated suppliers, making the supply chain vulnerable to disruptions due to regulatory actions, manufacturing issues, or quota limitations.

2. How does the DEA influence the supply of oxycodone hydrochloride API? The U.S. Drug Enforcement Administration (DEA) sets annual aggregate production quotas (APQs) for Schedule II controlled substances, including oxycodone hydrochloride, which limits the total amount that can be manufactured or imported into the U.S. each year.

3. What are the essential criteria for qualifying a new supplier of oxycodone hydrochloride API? Essential criteria include demonstrated compliance with DEA and FDA regulations, robust Good Manufacturing Practices (GMP), established quality management systems, secure supply chain protocols, and sufficient manufacturing capacity.

4. Can XTAMPZA ER manufacturers produce their own oxycodone hydrochloride API? While technically possible, in-house API manufacturing of controlled substances like oxycodone hydrochloride is highly complex and capital-intensive due to stringent regulatory requirements, specialized infrastructure, and significant security demands, making it rare for most pharmaceutical companies.

5. What is the typical geographic distribution of major oxycodone hydrochloride API manufacturers? Major manufacturers are predominantly located in North America and Europe, with facilities subject to rigorous oversight by regulatory bodies like the FDA and EMA.

Citations

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act (CSA). Retrieved from [DEA website] [2] International Narcotics Control Board. (n.d.). Role of the INCB. Retrieved from [INCB website] [3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA website] [4] Mallinckrodt Pharmaceuticals. (n.d.). Our Products - Active Pharmaceutical Ingredients. Retrieved from [Mallinckrodt website] [5] Perrigo Company plc. (n.d.). API Manufacturing. Retrieved from [Perrigo website] [6] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Teva website] [7] Johnson & Johnson. (n.d.). Noramco Overview. Retrieved from [Johnson & Johnson website]